Autolus Therapeutics plc (AUTL) — Financial statements
Income statement, balance sheet, and cash flow for Autolus Therapeutics plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 76↑646.7% | 10↑496.0% | 2↓72.6% | 6↑311.0% | 2 | |
| Cost of Revenue | 97↓31.5% | 141 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -21↑83.9% | -131↓7809.1% | 2↓72.6% | 6↑311.0% | 2 | |
| Operating Expenses | ||||||
| R&D Expenses | 129↓18.7% | 158↑21.2% | 130↑11.2% | 117↑5.9% | 111 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 47↑46.5% | 32↑0.1% | 32 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 132 | 0.00↓100.0% | 47↑46.5% | 32↑0.1% | 32 | |
| Other Expenses | 0.00↑100.0% | -48↓1240.9% | 4↑2613.9% | -0.17↑79.8% | -0.82 | |
| Operating Expenses | 260↑135.6% | 111↓39.1% | 181↑21.7% | 149↑5.1% | 142 | |
| Total Costs & Expenses | 357↑41.9% | 252↑38.7% | 181↑21.7% | 149↑5.1% | 142 | |
| Operating Results | ||||||
| Operating Income | -281↓16.6% | -241↓34.3% | -180↓25.8% | -143↓1.8% | -140 | |
| Depreciation & Amortization | 10↑27.5% | 8↑17.5% | 7↓11.5% | 7↓12.2% | 8 | |
| EBITDA | -272↓16.5% | -233↓48.7% | -157↓18.5% | -132↑0.2% | -132 | |
| EBIT | -281↓16.9% | -241↓47.4% | -163↓17.0% | -140↑0.9% | -141 | |
| Interest & Other Income | ||||||
| Net Interest Income | -18↓176.9% | 23↑173.1% | -32↓338.5% | -7↓753.7% | -0.84 | |
| Interest Income | 19↓41.2% | 32↑139.6% | 14↑690.7% | 2↑551.9% | 0.26 | |
| Interest Expense | 37↑295.5% | 9↓79.4% | 45↑406.1% | 9↑705.9% | 1 | |
| Non-Operating Income | 0.00↑100.0% | -0.64↑96.1% | -16↓406.5% | -3↓678.0% | 0.56 | |
| Other Income / Expenses | -15↓169.1% | 22↑177.7% | -29↓405.8% | -6↓241.0% | -2 | |
| Income Before Tax | -297↓35.5% | -219↓5.1% | -208↓40.3% | -149↓4.6% | -142 | |
| Income Tax Expense | -9↓666.0% | 2↑8142.1% | -0.02↓107.0% | 0.27↑369.0% | 0.06 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -288↓30.6% | -221↓5.9% | -208↓40.0% | -149↓4.7% | -142 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -288↓30.6% | -221↓5.9% | -208↓40.0% | -149↓4.7% | -142 | |
| Bottom-Line Net Income | -288↓30.6% | -221↓5.9% | -208↓40.0% | -149↓4.7% | -142 | |
| EPS (Basic) | -1.08↓24.1% | -0.87↑27.5% | -1.20↑23.6% | -1.57↑20.3% | -1.97 | |
| EPS (Diluted) | -1.08↓24.1% | -0.87↑27.5% | -1.20↑23.6% | -1.57↑20.3% | -1.97 | |
| Weighted Average Shares | 266↑4.3% | 255↑46.7% | 174↑83.1% | 95↑31.8% | 72 | |
| Weighted Average Diluted Shares | 266↑4.3% | 255↑46.7% | 174↑83.1% | 95↑31.8% | 72 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.